Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • FBIOP Announcements
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Aug 14, 2018

Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Aug 13, 2018

Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer

Aug 13, 2018

Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency

Aug 13, 2018

Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Aug 09, 2018

Mustang Bio to Present at 10th Annual Bioprocessing Summit

Aug 09, 2018

Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Aug 07, 2018

Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Pennsylvania to Advance AAV Gene Therapy Technology

Aug 06, 2018

Mustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T)

Jul 19, 2018

Fortress Biotech Announces Cyprium Therapeutics’ CUTX-101 (Copper Histidinate) Granted FDA Fast Track Designation for Treatment of Classic Menkes Disease

Jul 02, 2018
RSS
  • Prev
    • 1...
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    • 58
    • 59
    • 60
    • 61
    • ...71
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap